Stocklytics Platform
Asset logo for symbol AVRO
Avrobio
AVRO68
$33.020.00%$0.00
High Growth
Asset logo for symbol AVRO
AVRO68

$33.02

0.00%

Performance History

Chart placeholder
Key Stats
Open$29.96
Prev. Close$33.02
EPS8.28
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$5.23M
LOWHIGH
Day Range29.69
33.30
52 Week Range1.40
33.30
Ratios
Revenue-
EBITDA Margin %-
EPS8.28

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Avrobio (AVRO)

Avrobio Inc (AVRO) is a leading gene therapy company focused on the development of transformational lentiviral-based gene therapies for patients with severe genetic diseases. Their mission is to provide patients with life-changing treatments that address the underlying causes of their diseases. With a strong pipeline of candidate therapies targeting rare genetic diseases, Avrobio is at the forefront of the gene therapy revolution. They employ a proprietary approach known as plato that combines gene therapy with ex vivo selection, enabling them to deliver a potentially curative treatment to patients. This innovative platform has the potential to transform the lives of thousands of patients worldwide.
Avrobio Inc's stock price history reflects the company's rapid growth and potential. Since going public, the stock has experienced significant volatility, with shares reaching highs and lows based on investor sentiment and market conditions. However, the long-term outlook for Avrobio remains positive, as their gene therapies have the potential to revolutionize the treatment of rare genetic diseases. As the company continues to advance its pipeline and deliver positive clinical trial results, investor confidence is expected to increase, driving the stock price higher. The market cap of Avrobio Inc reflects the value that investors place on the company's potential. As of the latest data, Avrobio has a market cap of $X billion, indicating strong investor interest and confidence in the company's future prospects.
Sector
Healthcare
Industry
Biotechnology
CEO
Headquarters
Cambridge
Employees
78
Exchange
NASDAQ
add Avrobio  to watchlist

Keep an eye on Avrobio

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Avrobio 's (AVRO) price per share?

The current price per share for Avrobio (AVRO) is $33.02. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Avrobio (AVRO)?

For Avrobio (AVRO), the 52-week high is $33.3, which is 0.85% from the current price. The 52-week low is $1.4, the current price is 2.26K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Avrobio (AVRO) a growth stock?

Avrobio (AVRO) has shown an average price growth of -4.97% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Avrobio as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Avrobio (AVRO) stock price performance year to date (YTD)?

As of the latest data, Avrobio (AVRO) has a year-to-date price change of 91.09%. Looking at a longer horizon, the five-year price change stands at -86.44%.
help

Is Avrobio (AVRO) a profitable company?

Avrobio (AVRO) has a net income of $12.16M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$71.67M. Furthermore, the EBITDA is -$48.91M.
help

What is the market capitalization of Avrobio (AVRO)?

Avrobio (AVRO) has a market capitalization of $5.24M. The average daily trading volume is 228.82K, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level